Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance
Diffuse large B-cell lymphoma (DLBCL) is one of the most common non-Hodgkin lymphomas in adults. The disease is very heterogeneous in its presentation, that is DLBCL patients may differ from each other not only in regard to histology of tissue infiltration, clinical course or response to treatment,...
Main Authors: | Agata Majchrzak, Magdalena Witkowska, Piotr Smolewski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-09-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/19/9/14304 |
Similar Items
-
PI3K/Akt/mTOR inhibitors in breast cancer
by: Joycelyn JX Lee, et al.
Published: (2015-12-01) -
Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products
by: Iksen, et al.
Published: (2021-07-01) -
Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: Emerging Therapeutic Opportunities
by: Paul A Hubbard, et al.
Published: (2014-12-01) -
Editorial for the Research Topic "Targeting PI3K/mTOR signaling in cancer"
by: Alexandre eArcaro
Published: (2014-04-01) -
Targeting PI3K/mTOR signaling in cancer
Published: (2014)